The Prestige Biopharma Group said Thursday that it would participate in BIO International Convention 2023, the largest international biopharmaceutical event in Boston, Mass., from June 5 to 8.

Prestige Biopharma Chairwoman Park So-yeon and Prestige Biologics CEO Hyun Deok-hun will attend the event, overseeing the building of their exhibition booth. An OLED touchscreen will be installed inside the booth to showcase the company’s manufacturing facility in Osong, North Chungcheong Province.

The group’s other top managers, including Vice Chairman Kim Jin-woo and Michael Rupert, executive director in charge of developing projects, will also participate in BIO 2023. During the event, the Prestige Biopharma Group will network with many global pharmaceutical companies, the group said.

Chairwoman Park will conduct an IR pitch to global venture capitalists at the Korea Biotech Partnership (KBTP), an investor relations event organized by KoreaBio, an industry association. The group plans to conduct promotional activities through corporate introduction presentations at the K-Startup event, also to be organized by KoreaBio.

The Prestige Biopharma Group plans to emphasize that it is a group with a “full value chain,” which integrates the entire life cycle of pharmaceuticals, from the research and development stage to production.

Prestige Biopharma will showcase its various R&D achievements, including HD201, a Herceptin biosimilar that is pending resubmission to the European Medicines Agency (EMA), while Prestige Biologics will showcase its 154,000-liter contract development manufacturing organization (CDMO) capacity to find new customers.

“The main purpose of this event is to actively participate in IR events organized by KoreaBio and make a strong impression of our two companies as K-Bio frontrunners,” a company official said. “Another goal is to introduce the company to more companies, demonstrate the stable manufacturing capabilities required by our customers, and get results that lead to actual contract manufacturing.”